Image generated with AI
Pharma 4.0 is reshaping how medicines are discovered, developed, manufactured, and delivered. Artificial intelligence, cloud, and connected data are accelerating innovation across the pharmaceuticals (pharma) value chain, but they also increase the demand for security, compliance, and control. The sovereign cloud provides a trusted digital foundation that enables pharma companies to innovate confidently while protecting critical data.
Europe's pharma industry stands at the intersection of scientific innovation and digital transformation. Breakthrough therapies, precision medicine, advanced biologics, and personalized healthcare are changing how medicines are discovered, manufactured, and delivered. At the same time, AI, automation, and connected data ecosystems are accelerating a new era—Pharma 4.0.
Inspired by the principles of Industry 4.0, Pharma 4.0 extends digital transformation across the pharma value chain, from research and development to clinical trials, manufacturing, quality management, supply chains, and post-market surveillance. Intelligent technologies are helping organizations reduce development timelines, improve product quality, strengthen regulatory compliance, and create more resilient operations.
Yet, as pharma companies embrace AI and cloud technologies, one question has become increasingly important: how can innovation be accelerated without compromising control over critical data, intellectual property, and regulatory obligations?
This is where digital sovereignty is becoming a strategic differentiator.
Cloud computing has become an essential enabler of pharmaceutical innovation. Organizations rely on cloud platforms to accelerate drug discovery, support clinical research, modernize manufacturing, and connect global operations. AI applications, digital twins, and advanced analytics all depend on scalable cloud infrastructure.
However, for pharma companies, innovation cannot come at the expense of control. Clinical trial data, patient information, manufacturing recipes, intellectual property, and regulatory submissions are among an organization's most valuable digital assets. At the same time, regulations such as GDPR, GxP, the EU AI Act, the European Health Data Space (EHDS), and NIS2 continue to raise expectations for data governance, security, and operational resilience.
For organizations operating regulated GxP environments, additional challenges are emerging around computer system validation (CSV), AI governance, auditability, and maintaining trust in AI-assisted processes. As generative AI becomes more deeply embedded in research, manufacturing, quality, and regulatory workflows, ensuring transparency, traceability, and validated operation is becoming just as important as protecting the underlying data.
The challenge is no longer simply moving workloads to the cloud. It is ensuring that data, AI models, and critical applications remain secure, compliant, and under organizational control. The sovereign cloud bridges this gap, enabling pharma companies to accelerate innovation while meeting evolving regulatory and business requirements.
Leading pharma companies are already demonstrating this shift. During the COVID-19 pandemic, Pfizer accelerated vaccine development by combining cloud computing, advanced analytics, and AI-enabled collaboration across its global research and manufacturing teams.1
More recently, Roche and Novartis have continued expanding cloud-first digital strategies to support AI-driven research, real-world evidence, and connected operations. This illustrates how cloud has become a strategic enabler rather than simply an IT platform.2
Image generated with AI
Pharma 4.0 extends digital transformation across the pharmaceutical value chain by connecting research, clinical development, manufacturing, quality, supply chains, and commercial operations through intelligent data and automation.
Every stage generates vast amounts of information, from laboratory research and genomic sequencing to electronic batch records, manufacturing execution systems (MES), quality management systems (QMS), pharmacovigilance, and real-world evidence. When connected, these data sources provide the foundation for AI-driven decision-making and continuous improvement.
Yet many organizations still operate fragmented technology landscapes built over decades. Data remains isolated across laboratory systems, enterprise applications, and manufacturing environments, making it difficult to scale AI beyond individual projects. Modernizing applications, integrating data, and establishing trusted governance are becoming essential steps toward realizing the full promise of Pharma 4.0.
A good example is AstraZeneca, which has invested heavily in creating connected digital platforms that integrate research, manufacturing, and commercial data.3 By reducing data silos and improving interoperability, the company has been able to strengthen AI-driven insights across drug discovery and clinical development while supporting more agile decision-making.
As pharmaceutical organizations connect research, clinical, manufacturing, and commercial operations through shared platforms and AI-driven workflows, the complexity of governing sensitive data increases significantly. Data often moves across multiple systems, partners, and jurisdictions, creating new challenges around security, compliance, and control. This is why digital sovereignty is becoming an increasingly important foundation for Pharma 4.0, helping organizations innovate while maintaining trust in how critical data and AI-enabled processes are managed.
Digital sovereignty is often viewed as a compliance requirement. In reality, it is an enabler of secure innovation. For pharma companies, sovereignty can be understood across three dimensions:
Data sovereignty ensures that sensitive research data, clinical information, manufacturing records, and intellectual property remain protected under European jurisdiction, with organizations retaining control over encryption keys and data access.
Operational sovereignty strengthens resilience through secure European operations, business continuity, disaster recovery, and trusted management of critical pharma systems.
Technology sovereignty enables organizations to modernize without becoming dependent on a single cloud provider, supporting flexible hybrid and multi-cloud architectures that evolve alongside business and regulatory requirements.
Together, these dimensions create the trusted digital foundation needed to support Pharma 4.0.
AI is rapidly becoming embedded throughout the pharmaceutical lifecycle. Several leading pharmaceutical companies are already moving beyond experimentation. Sanofi, through its strategic partnership with OpenAI and Formation Bio, is using generative AI (GenAI) to accelerate drug development and improve how medicines move from research to patients.4 Novo Nordisk is applying AI and advanced analytics to optimize manufacturing and supply chain operations5, while Roche continues expanding AI-assisted diagnostics and personalized healthcare solutions.6
Researchers are using GenAI to accelerate drug discovery, identify therapeutic targets, and analyze scientific literature. Clinical teams are exploring AI to optimize trial design and improve patient recruitment. Pharma manufacturing organizations are adopting intelligent quality inspection, predictive maintenance, and process optimization, while regulatory teams are beginning to automate document preparation and compliance workflows. AI agents and intelligent assistants are emerging to support knowledge workers by streamlining repetitive tasks, surfacing insights, and enabling faster decision-making across the enterprise.
Many pharma companies initially approached digital transformation as large-scale modernization programs. Today, a more pragmatic strategy is emerging. Rather than modernizing every application simultaneously, organizations begin with high-value business use cases, such as AI-assisted quality investigations, digital batch release, predictive maintenance, clinical trial optimization, or accelerated drug discovery. These initiatives deliver measurable value while progressively modernizing the applications, data platforms, and cloud infrastructure needed to support a broader transformation.
This iterative approach enables organizations to advance Pharma 4.0 while reducing complexity and delivering faster business outcomes. This business-first approach is increasingly reflected across the industry. Rather than treating digital transformation as a single program, organizations are progressively scaling successful use cases into enterprise-wide capabilities; a defining characteristic of mature Pharma 4.0 strategies.
The need for sovereign AI infrastructure is also growing as pharma companies adopt larger foundation models for molecular simulation, protein design, and clinical research. These workloads require significantly greater computing capacity while maintaining strict governance over intellectual property and sensitive health data. Recognizing this need, Deutsche Telekom, and T-Systems, together with NVIDIA and SAP, launched Europe's first Industrial AI Cloud in 2026. Hosted entirely in Germany, it significantly expands Europe's AI computing capacity while providing trusted infrastructure built around European standards for privacy, security, and operational control.
The Industrial AI Cloud represents an important step towards enabling these capabilities within trusted European infrastructure. By combining sovereign infrastructure with enterprise AI capabilities, organizations can accelerate innovation while maintaining confidence in how their data is governed and protected.
Technology modernization is becoming the foundation for successful Pharma 4.0 initiatives. Legacy systems continue to support critical business processes, but they were not designed for today's connected, AI-enabled operating models. Organizations increasingly require interoperable platforms capable of integrating research systems, manufacturing operations, enterprise applications, and analytics into a unified digital ecosystem.
Digital transformation increasingly extends to enterprise applications as well. Many pharma companies are modernizing SAP landscapes to create standardized, AI-ready business processes that connect R&D, manufacturing, quality, procurement, and finance. Clean core principles, SAP Business AI, and SAP Business Data Cloud are helping establish consistent data foundations while enabling innovation without increasing system complexity. Rather than replacing existing investments, organizations are building flexible digital foundations that support continuous innovation while maintaining regulatory compliance.
Delivering Pharma 4.0 requires expertise that spans cloud, AI, cybersecurity, enterprise applications, and regulated operations. T-Systems supports pharma companies throughout this transformation journey, from cloud strategy and application modernization to SAP transformation, sovereign cloud, AI-ready data platforms, and managed services. Whether organizations are modernizing SAP environments, preparing data for AI, or building hybrid and sovereign cloud architectures, the focus remains the same: creating secure digital foundations that accelerate innovation while meeting regulatory obligations.
Through solutions such as T Cloud, sovereign cloud services, SAP transformation offerings including RISE with SAP, AI-powered managed services, and the Industrial AI Cloud, T-Systems helps organizations modernize at their own pace while balancing innovation, resilience, and digital sovereignty.
The pharma industry is entering a new era where scientific innovation and digital transformation are becoming inseparable.
Organizations that successfully combine Pharma 4.0, AI, and sovereign cloud will be better positioned to accelerate research, improve manufacturing, strengthen regulatory compliance, and build more resilient supply chains.
Digital sovereignty is no longer simply about protecting data. It is about creating trusted digital environments where innovation can scale with confidence. As AI becomes embedded across the pharma value chain, the sovereign cloud provides a secure foundation, while modern transformation platforms enable organizations to unlock the full potential of Pharma 4.0, delivering better business outcomes today while preparing for the next generation of intelligent pharma innovation.
1 Accelerating Digital Technology for the COVID-19 Vaccine Rollout, Pfizer, March 2022, www.pfizer.com
2 Top 5 Digitally Innovative Pharmaceutical Companies in Europe, Intuition Labs, July 2026, www.intuitionlabs.ai
3 Data Science & Artificial Intelligence: Unlocking new science insights, AstraZeneca, December 2024, www.astrazeneca.com
4 Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration, Sanofi, May 2024, press release
5 Novo Nordisk, OpenAI Bring AI Into Core Operations to Accelerate Time to Market, ERP Today, April 2026, www.erp.today
6 Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions, Roche, March 2026, press release
